AR081261A1 - Metodos para tratar afecciones virales - Google Patents

Metodos para tratar afecciones virales

Info

Publication number
AR081261A1
AR081261A1 ARP110101835A ARP110101835A AR081261A1 AR 081261 A1 AR081261 A1 AR 081261A1 AR P110101835 A ARP110101835 A AR P110101835A AR P110101835 A ARP110101835 A AR P110101835A AR 081261 A1 AR081261 A1 AR 081261A1
Authority
AR
Argentina
Prior art keywords
optionally substituted
alkyl
hydrogen
hydroxyl
compounds
Prior art date
Application number
ARP110101835A
Other languages
English (en)
Original Assignee
Ptc Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ptc Therapeutics Inc filed Critical Ptc Therapeutics Inc
Publication of AR081261A1 publication Critical patent/AR081261A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/42—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum viral
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Compuestos que inhiben en forma selectiva la replicación viral o la producción del ARN o ADN viral. la proteína viral o los efectos citopáticos inducidos por el virus y las composiciones que comprenden estos compuestos. Métodos para inhibir la replicación viral o la producción de ARN o ADN viral, la proteína viral o los efectos citopáticos inducidos por el virus utilizando estos compuestos y los métodos para tratar infecciones virales que involucran la administración de estos compuestos. Los compuestos se pueden administrar en forma de terapia de un único agente o en combinación con una o más terapias adicionales a un humano que necesita de este tratamiento. Reivindicación 1: Un método para tratar una infección viral en un humano que lo necesita caracterizado porque comprende la administración al humano de una cantidad eficaz de un compuesto que tiene la fórmula (1), o su sal, racemato, tautómero o estereoisómero aceptable desde el punto de vista farmacéutico, donde, W es hidrógeno o halógeno; X es hidrógeno; alquilo C1-8 opcionalmente sustituido; hidroxilo; halógeno; tioéter; sulfinilo; sulfonilo; ciano; o C1-8 opcionalmente sustituido; Y es hidrógeno; alquilo C1-8 opcionalmente sustituido; o halógeno; Z es hidrógeno; o alquilo C1-8; A es CH o N; B es CH o N, siempre que al menos uno de A o B sea N, y que cuando A sea N, B sea CH; R1 es hidroxilo; alquilo C1-8 opcionalmente sustituido, alquenilo C2-8; alquinilo C2-8; heterociclilo opcionalmente sustituido; heteroarilo opcionalmente sustituido; o arilo opcionalmente sustituido; R2 es hidrógeno; hidroxilo; halógeno; heteroarilo opcionalmente sustituido; alquilo C1-8 opcionalmente sustituido; -C(O)-Rc; -C(O)O-Rd; -C(O)C(O)-NH-Rd; -C(O)C(O)-O-Rd; -C(O)-N(RdRd); -C(S)-N(RdRd); -C(S)-O-Re; -S(O2)Re; -C(NRe)-S-Re; o -C(S)-S-Rf; Rc es hidrógeno; amino opcionalmente sustituido; arilo opcionalmente sustituido; C(O)-Rn; heterociclilo opcionalmente sustituido; heteroarilo; tiazolamino; alquilo C1-8 opcionalmente sustituido; cicloalquilo; o alquenilo C2-8 opcionalmente sustituido; Rd es en cada aparición independientemente hidrógeno; alquenilo C2-8; alquinilo C2-8; arilo opcionalmente sustituido; cicloalquilo; o alquilo C1-8 opcionalmente sustituido; Re es hidrógeno; alquilo C1-8 opcionalmente sustituido; cicloalquilo opcionalmente sustituido; o arilo opcionalmente sustituido; Rf es alquilo C1-8 opcionalmente sustituido; Rn es hidroxilo; alcoxi C1-8; amino; arilo opcionalmente sustituido; R3 es hidrógeno; o -C(O)-Rg; y Rg es hidroxilo; amino opcionalmente sustituido; heteroarilo opcionalmente sustituido; o heterociclilo opcionalmente sustituido.
ARP110101835A 2010-05-27 2011-05-27 Metodos para tratar afecciones virales AR081261A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US34918610P 2010-05-27 2010-05-27

Publications (1)

Publication Number Publication Date
AR081261A1 true AR081261A1 (es) 2012-07-18

Family

ID=45004375

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP110101835A AR081261A1 (es) 2010-05-27 2011-05-27 Metodos para tratar afecciones virales

Country Status (4)

Country Link
US (1) US20130171103A1 (es)
AR (1) AR081261A1 (es)
TW (1) TW201141864A (es)
WO (1) WO2011150162A1 (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3718405A1 (en) 2009-05-27 2020-10-07 PTC Therapeutics, Inc. Methods for treating cancer and non-neoplastic conditions
JP6616790B2 (ja) * 2014-06-27 2019-12-04 ノグラ ファーマ リミテッド アリール受容体モジュレーターならびにその作製および使用方法
WO2016030863A1 (en) 2014-08-29 2016-03-03 Glaxosmithkline Intellectual Property Development Limited Compounds and methods for treating viral infections
WO2016069949A1 (en) * 2014-10-29 2016-05-06 Virginia Tech Intellectual Properties, Inc. Compositions and formulations of methylerthritol phosphate pathway inhibitors and uses thereof
SG10202100799PA (en) 2014-12-18 2021-03-30 Hoffmann La Roche TETRAHYDRO-PYRIDO[3,4-b]INDOLE ESTROGEN RECEPTOR MODULATORS AND USES THEREOF
US20180098972A1 (en) 2015-01-26 2018-04-12 Children's Medical Center Corporation Treatment of infectious diseases
US20180002344A1 (en) 2016-06-16 2018-01-04 Genentech, Inc. Heteroaryl estrogen receptor modulators and uses thereof
KR20200035292A (ko) 2017-08-01 2020-04-02 피티씨 테라퓨틱스, 인크. 혈액 암 치료에 사용하기 위한 dhodh 억제제
CN109867662B (zh) * 2018-02-07 2020-08-14 南方医科大学 一种咔唑β-氨基醇类衍生物及其制备方法和用途
UA128114C2 (uk) 2018-06-21 2024-04-10 Ф. Хоффманн-Ля Рош Аг Тверді форми 3-((1r,3r)-1-(2,6-дифтор-4-((1-(3-фторпропіл)азетидин-3-іл)аміно)феніл)-3-метил-1,3,4,9-тетрагідро-2h-піридo[3,4-b]індол-2-іл)-2,2-дифторпропан-1-олу і способи одержання конденсованих трициклічних сполук, що містять заміщене фенільне або піридинільне угруповання, в тому числі способи їх застосування
WO2020247860A1 (en) * 2019-06-06 2020-12-10 University Of Maryland, Baltimore Broad spectrum antiviral compounds targeting the ski complex
TW202207922A (zh) * 2020-05-08 2022-03-01 美商 Ptc 治療公司 用於治療covid-19之二氫乳清酸脫氫酶(dhodh)抑制劑
AU2021309106A1 (en) * 2020-07-11 2023-03-09 The Regents Of The University Of California Compositions and methods for inhibiting and treating coronavirus infections
WO2022140744A1 (en) 2020-12-23 2022-06-30 Recurium Ip Holdings, Llc Estrogen receptor modulators
CN114159434B (zh) * 2021-11-04 2023-06-20 中山亿维迪科技有限公司 一种含氮多环类芳香化合物在制备抗疱疹病毒药物中的应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7767689B2 (en) * 2004-03-15 2010-08-03 Ptc Therapeutics, Inc. Carboline derivatives useful in the treatment of cancer
WO2007002051A1 (en) * 2005-06-22 2007-01-04 Smithkline Beecham Corporation Carboline derivatives and their use as inhibitors of flaviviridae infections
JP2009526070A (ja) * 2006-02-09 2009-07-16 シェーリング コーポレイション Ｈｃｖプロテアーゼ阻害薬とｈｃｖポリメラーゼ阻害薬との組み合わせ、ならびにそれらに関連する処置の方法

Also Published As

Publication number Publication date
TW201141864A (en) 2011-12-01
WO2011150162A1 (en) 2011-12-01
US20130171103A1 (en) 2013-07-04

Similar Documents

Publication Publication Date Title
AR081261A1 (es) Metodos para tratar afecciones virales
EA201891876A1 (ru) Тетрациклические пиридоновые соединения в качестве противовирусных средств
EA201890735A1 (ru) Модуляторы корового белка вируса гепатита b
UY37133A (es) Derivados de pirazolo[1,5-a]pirazin-4-ilo
PE20180232A1 (es) Derivados de indol mono o disustituidos como inhibidores de la replicacion viral del dengue
AR111820A1 (es) Derivados de indolina sustituidos como inhibidores de la replicación de virus del dengue
BR112015021027A8 (pt) compostos terapêuticos, seus usos, e composições farmacêuticas
DOP2015000240A (es) 3- pirimidin- 4- il- oxazolidin- 2- onas como inhibidores de idh mutante
AR111314A1 (es) Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue
AR108046A1 (es) Derivados de indolina sustituidos como inhibidores de la replicación viral del dengue
AR095034A1 (es) El uso de los agonistas del receptor 2 del péptido formilo para el tratamiento de las enfermedades inflamatorias oculares
BR112015028879A8 (pt) compostos derivados heterocíclicos, composição farmacêutica compreendendo os referidos compostos e usos dos mesmos
CR20140086A (es) Tratamientos de combinación para hepatitis c
EA201791916A1 (ru) 2'-замещенные карбануклеозидные аналоги для противовирусного лечения
EA201591328A1 (ru) Замещенные гетероциклом тетрациклические соединения и способы их применения для лечения вирусных заболеваний
EA201692506A3 (ru) Ингибиторы репликации вирусов гриппа
BR112015025766A2 (pt) derivado de nucleosídeo altamente ativo para o tratamento de hcv
CO2019010292A2 (es) Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue
ECSP14013315A (es) Inhibidores de aplicación viral
EA201892216A1 (ru) Замещенные производные индолина в качестве ингибиторов репликации вирусов денге
BR112012000287B8 (pt) composição farmacêutica para um inibidor de protease viral de hepatite c
AR099632A1 (es) Tratamiento de una infección viral de hepatitis c, que usa una combinación de compuestos
AR111878A1 (es) Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue
BR112015024552A2 (pt) compostos de fórmula (a), composição farmacêutica, métodos para a preparação do composto e métodos de tratamento ou prevenção de infecções
RU2013150861A (ru) Фармацевтическая композиция, содержащая производные глутаримидов, и их применение для лечения эозинофильных заболеваний

Legal Events

Date Code Title Description
FA Abandonment or withdrawal